Seroprevalence of herpes simplex virus types 1 and 2 in Nigeria: a systematic review and meta-analyses

Pathog Glob Health. 2019 Jul;113(5):229-237. doi: 10.1080/20477724.2019.1678938. Epub 2019 Oct 24.

Abstract

A source of comprehensive information on the prevalence of herpes simplex virus type 1 and 2 (HSV-1 and HSV-2) can help researchers and policymakers address HSV related burden in the society. At the moment, this is not readily available. This study aims to fill this gap by attempting to estimate the seroprevalence of HSV-1 and HSV-2 infections in Nigeria on the basis of published data. A systematic review and meta-analysis including cross-sectional studies on HSV-1 and HSV-2 in Nigeria was conducted. Electronic databases including PubMed/MEDLINE, CENTRAL, African Journals Online (AJOL), ScienceDirect, WHO-Afro Library, WHO-IRIS and African Index Medicus were searched for English Language publications on HSV-1 and HSV-2. Seven relevant publications were identified. Seroprevalence measures of 3 and 23 for HSV-1 and HSV-2, respectively, were extracted. The pooled mean seroprevalences for HSV-1 and HSV-2 were 74.0% (37.4-99.4%) and 63.4% (56.1-70.4%) respectively. The mean seroprevalence of HSV-1 was higher among females, 82.4% (n = 509, CI, 36.6-100.0%), than males, 54.5% (n = 198, CI, 47.6-61.4%). The mean seroprevalence of HSV-2 were 51.8% (n = 1414, CI: 39.4-64.0%) and 86.5% (n = 162, CI: 80.8-91.3%) among healthy and clinical populations, respectively. The study was limited by the paucity of quality studies, variations in diagnostic methods and high heterogeneity in seroprevalence estimates. In conclusion, the seroprevalence of HSV-1 and HSV-2 remain high in Nigeria. Large and representative national epidemiological surveys covering all regions and specific groups are recommended.

Keywords: Herpes simplex virus; infection; meta-analysis; seroprevalence; systematic review.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Antibodies, Viral / blood*
  • Female
  • Herpes Simplex / epidemiology*
  • Herpesvirus 1, Human / immunology*
  • Herpesvirus 2, Human / immunology*
  • Humans
  • Male
  • Nigeria / epidemiology
  • Seroepidemiologic Studies
  • Sex Factors

Substances

  • Antibodies, Viral

Grants and funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.